What's in Pacira Pharmaceuticals, Inc's pipeline?

Pacira Pharmaceuticals, Inc has 19 drugs in our index: 13 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 4 in Phase 1.

Which companies overlap with Pacira Pharmaceuticals, Inc's portfolio?

Top competitors by shared drug class: Wake Forest University Health Sciences, The Cleveland Clinic, Tianjin Medical University General Hospital, University of California, Davis, Aultman Health Foundation.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/pacira-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Pacira Pharmaceuticals, Inc — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pacira Pharmaceuticals, Inc pipeline: 13 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

13 marketed 0 filed 1 Phase 3 1 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Infiltration - EXPAREL	Infiltration - EXPAREL	marketed	Long-acting local anesthetic	Voltage-gated sodium channels	Anesthesia / Pain Management
IV morphine sulfate or Sponsor-approved equivalent	IV morphine sulfate or Sponsor-approved equivalent	marketed
EXPAREL Infiltration	EXPAREL Infiltration	marketed
Exparel TAP + multi-modal pain regimen	Exparel TAP + multi-modal pain regimen	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels	Pain Management / Anesthesia
Exparel + Bupivacaine	Exparel + Bupivacaine	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels	Anesthesia / Pain Management
EXPAREL 40 mL	EXPAREL 40 mL	marketed
Bupivacaine SNB	Bupivacaine SNB	marketed	Local anesthetic	Voltage-gated sodium channels	Anesthesia/Pain Management
On-Q Pain Ball	On-Q Pain Ball	marketed	Local anesthetic infusion pump	Voltage-gated sodium channels (via bupivacaine)	Pain Management / Anesthesia
EXPAREL 20 mL	EXPAREL 20 mL	marketed
Bupivacaine FNB	Bupivacaine FNB	marketed	Local anesthetic	Voltage-gated sodium channels	Pain Management / Regional Anesthesia
Instillation - EXPAREL	Instillation - EXPAREL	marketed	Long-acting local anesthetic	Voltage-gated sodium channels	Pain Management / Anesthesia
EXPAREL and bupivacaine HCl	EXPAREL and bupivacaine HCl	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels	Pain Management / Anesthesia

Therapeutic area mix

Pain Management / Anesthesia · 5
Anesthesia / Pain Management · 2
Anesthesia/Pain Management · 1
Pain Management / Regional Anesthesia · 1
Pain management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Wake Forest University Health Sciences · 2 shared drug classes
The Cleveland Clinic · 2 shared drug classes
Tianjin Medical University General Hospital · 2 shared drug classes
University of California, Davis · 2 shared drug classes
Aultman Health Foundation · 1 shared drug class
B.P. Koirala Institute of Health Sciences · 1 shared drug class
Ain Shams University · 1 shared drug class
Atlantic Health System · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Pacira Pharmaceuticals, Inc:

Cite this brief

Drug Landscape (2026). Pacira Pharmaceuticals, Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pacira-pharmaceuticals-inc. Accessed 2026-05-17.